First-Ever Blood-Based Test Detects Range of Cancers and Identifies Whether They Have Spread

A new minimally invasive and inexpensive blood test can identify cancer in patients with non-specific symptoms.

Scientists at the University of Oxford (Oxford, UK) have developed the new type of blood test that can be used to detect a range of cancers and whether these cancers have spread (metastasized) in the body. The scientists conducted a study in which they analyzed samples from 300 patients with non-specific but concerning symptoms of cancer, such as fatigue and weight loss. The team assessed whether the test could distinguish patients with a range of solid tumors from those without cancer.

Their results showed that cancer was correctly detected in 19 out of every 20 patients with cancer using this test. In those with cancer, metastatic disease was identified with an overall accuracy of 94%. These results make this the first technology to be able to determine the metastatic status of a cancer from a simple blood test, without prior knowledge of the primary cancer type. The test shows promise to help clinicians detect cancer and assess cancer stage in the future.

Unlike many blood-based tests for cancer, which detect genetic material from tumors, this test uses a technique called NMR metabolomics, which uses high magnetic fields and radio waves to profile levels of natural chemicals (metabolites) in the blood. Healthy individuals, people with localized cancer, and people with metastatic cancer each have different profiles of blood metabolites, which can be detected and then analyzed by the researchers’ algorithms to distinguish between these states.

Cancers detected earlier are more likely to be treated successfully. This rapid and inexpensive test could help to overcome many barriers to the early detection of cancer, especially in patients that present with non-specific symptoms, which do not direct investigations towards a specific organ. The new test is not specific to a single cancer type and has shown promise in this traditionally challenging clinical context, including the potential to detect some cancers in the community before conventional imaging is performed. Future studies with larger patient cohorts will further evaluate this technique for the earlier detection of new cancers and potential clinical applications.

“Cancer cells have unique metabolomic fingerprints due to their different metabolic processes. We are only now starting to understand how metabolites produced by tumors can be used as biomarkers to accurately detect cancer,” said Dr. James Larkin, researcher on the study from the University of Oxford. “We have already demonstrated that this technology can successfully identify if patients with multiple sclerosis are progressing to the later stages of disease, even before trained clinicians could tell. It is very exciting that the same technology is now showing promise in other diseases, like cancer.”

“This work describes a new way of identifying cancer. The goal is to produce a test for cancer that any GP can request,” said Dr. Fay Probert, lead researcher of the study from the University of Oxford. “We envisage that metabolomic analysis of the blood will allow accurate, timely and cost-effective triaging of patients with suspected cancer, and could allow better prioritization of patients based on the additional early information this test provides on their disease.”

Related Links:
University of Oxford 

Visit expo >

Platinum Member

Xylazine Immunoassay Test

Xylazine ELISA

Magnetic Bead Separation Modules
MAG and HEATMAG

Complement 3 (C3) Test

GPP-100 C3 Kit

Gold Member

Automatic Western Blot Analyzer

Tenfly Phoenix Blot Analyzer